Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.

Producing bispecific antibodies at scale is notoriously difficult. See how Syngene achieved a 3X yield increase and 98.5% purity for Hinge Bio's GEM-DIMER™ platform in just seven months.

N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.

N-1 perfusion improves antibody production by increasing cell density, optimizing media and conditions, boosting yields up to 4.5× while maintaining quality and reducing manufacturing time and costs.

A platform-based upstream strategy increased monoclonal antibody titers fourfold, improving yield, efficiency, and scalability via optimized clones, process design, and rapid scale-up.

Gain insight into a first-time-right process that improved yield and scalability, advancing a vascular calcification inhibitor from lab scale to tox and GMP manufacturing for clinical development.

Looking to bring an innovative animal health product to market? See how we delivered end-to-end formulation development and rapid clinical supply manufacturing for complex multi-API products.

Process optimization delivered a scalable, cost-effective synthesis, increasing yield and reducing waste, solvents, and costs while enabling rapid transition from lab to cGMP manufacturing.

Outsourcing stability testing improved efficiency, reduced costs, and enhanced scalability, enabling robust lifecycle support, regulatory compliance, and optimized resource utilization across programs.

Process innovation reduced synthesis steps, increased yield, and improved chiral purity, enabling faster, scalable manufacturing of a pancreatic cancer therapy for clinical and commercial development.